Clinical characteristic | No (%) of all patients (n = 58) | Prognosis | P-value | Multivariate analysis | P-value | ||
---|---|---|---|---|---|---|---|
Poor (n = 16) | Well (n = 42) | Odds ratios | 95% CI | ||||
Gender | |||||||
Male | 40 (70.0) | 12 (75.0) | 28 (66.7) | 0.752 | – | – | – |
Female | 18 (30.0) | 4 (25.0) | 14 (33.3) | ||||
Age, years (means ± SD) | 61.1 ± 16.7 | 56.56 ± 14.45 | 62.76 ± 17.30 | 0.208 | – | – | – |
Age | |||||||
< 65 | 30 (51.7) | 10 (62.5) | 20 (47.6) | 0.311 | – | – | – |
≥ 65 | 28 (48.3) | 6 (37.5) | 22 (52.4) | ||||
Symptoms and signs | |||||||
Fever (> 39℃) | 31 | 6 (37.5) | 25 (59.5) | 0.133 | – | – | – |
Leukocytosis | 26 | 6 (37.5) | 20 (47.6) | 0.489 | – | – | – |
Thrombocytopenia | 34 | 13 (81.3) | 21 (50) | 0.031* | |||
Neutropenia | 19 | 7 (43.8) | 12 (28.6) | 0.271 | – | – | – |
Microbial findings | |||||||
Monomicrobial | 49 (84.5) | 16 (100.0) | 33 (78.6) | 0.051 | – | – | – |
Polymicrobial | 9 (15.5) | 0 (0.0) | 9 (21.4) | ||||
Antimicrobial susceptibility | |||||||
MDR | 9 (15.5) | 4 (25.0) | 5 (11.9) | 0.243 | – | – | – |
Non MDR | 49 (84.5) | 12 (75.0) | 37 (88.1) | ||||
Source of infection | |||||||
Community acquired | 34 (58.6) | 13 (81.3) | 21 (50) | 0.031* | 3.201 | 0.57–18.00 | 0.187 |
Nosocomial infection | 24 (41.4) | 3 (18.8) | 21 (50) | ||||
Co-morbidity | |||||||
Liver cirrhosis | 26 (44.8) | 11 (68.8) | 15 (35.7) | 0.024* | 7.41 | 1.32–41.55 | 0.023* |
Diabetes mellitus | 7 (12.1) | 2 (12.5) | 5 (11.9) | 1.000 | – | – | – |
Malignancy | 18 (31.0) | 6 (37.5) | 12 (28.6) | 0.538 | – | – | – |
Leukemia | 8 (13.8) | 3 (18.8) | 5 (1.9) | 0.672 | – | – | – |
Treatment | |||||||
inappropriate empirical antimicrobials | 15 (25.9) | 10 (62.5) | 5 (11.9) | 0.000* | 16.91 | 3.04–94.22 | 0.001* |
Clinical outcomes | |||||||
Septic shock | 14 | 11 (68.8) | 3 (7.1) | 0.000* | – | – | – |
Admission to ICU | 10 | 9 (90) | 1 (2.4) | 0.000* | – | – | – |
Length of stay in hospital, days | 17 (6–24.75) | 2.5 (1–6) | 19 (11.25–30) | 0.000* | – | – | – |